ROCKVILLE, Md.--(BUSINESS WIRE)--March 24, 2006--New Research Assay Found to Be Precise with Minimal “Hands On” Time, and Greatly Reduces Time to Detection Compared with Existing Methodologies. Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that preliminary data from a feasibility study using its fragile X research assay evaluated by one of its collaborators from Oregon Health and Science University will be presented in a poster session at the 2006 American College of Medical Genetics annual meeting in San Diego, CA.
